Low dose fluorometholone stops endothelial rejection after PKP

Article

Using 0.1% fluorometholone after penetrating keratoplasty (PKP) significantly reduces the chances of endothelial rejection.

Using 0.1% fluorometholone after penetrating keratoplasty (PKP) significantly reduces the chances of endothelial rejection, claims a study in Ophthalmology.

A randomized, non-blinded, clinical trial, led by Dr Jun Shimazaki, Department of Ophthalmology, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan, included 42 patients who underwent PKP. Each patient had been administered topical steroid eye drops and maintained graft clarity for over one year.

The participants were randomly assigned to two groups and were assessed for 12 months. Group was administered 0.1% of fluorometholone three times daily and group 2 were not administered any steroids.

In group 1 there were 17 patients who completed the trial and in group 2 there were 15 patients. Endothelial rejection was developed in 1 patient in group 1 and 6 patients in group 2 at an average of 5.2±4.5 after PKP.

There were no differences in visual acuity, intraocular pressure, epithelial damage, tear film break-up time, cataract progression, infection, or incidence of systemic side effects between the groups.

There were no adverse effects reported when using 0.1% fluorometholone and the study suggests using low dose corticosteroids even in low-risk cases.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.